An update on paediatric asthma

European Respiratory Review

Volumn 21, Issue 125, 2012, Pages 175-185

  Hedlin, Gunilla ^a   Konradsen, Jon ^a   Bush, Andrew ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHITINASE; CORTICOSTEROID; FLUTICASONE; IMMUNOGLOBULIN E; LEBRIKIZUMAB; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NITRIC OXIDE; OMALIZUMAB; PITRAKINRA; PLACEBO; RESLIZUMAB; VITAMIN D;

ADD ON THERAPY; ALLERGIC ASTHMA; ARTICLE; ASTHMA; BLOOD ANALYSIS; BREATH ANALYSIS; CHILD HEALTH CARE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; EOSINOPHIL COUNT; EUROPE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG LAVAGE; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PARENTAL BEHAVIOR; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; RHINITIS; RHINOSINUSITIS; RHINOVIRUS; SPIROMETRY; SPUTUM ANALYSIS; UNSPECIFIED SIDE EFFECT; URINALYSIS; VITAMIN D DEFICIENCY; VOCAL CORD DISORDER; WHEEZING;

ADOLESCENT; AGE FACTORS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; COMORBIDITY; HUMANS; INFANT; LUNG; MEDICATION ADHERENCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84865738918     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00003212     Document Type: Article

References (155)

1. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926-938.
2. Krishnan JA, Lemanske RF Jr, Canino GJ, et al. Asthma outcomes: symptoms. J Allergy Clin Immunol 2012; 129: Suppl. 3, S124-S135.
3. He XY, Simpson JL, Wang F. Inflammatory phenotypes in stable and acute childhood asthma. Paediatr Respir Rev 2011; 12: 165-169.
4. Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol 2012; 129: 974-982.
5. Bousquet J, Anto J, Auffray C, et al. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy 2011; 66: 596-604.
6. Anto JM, Pinart M, Akdis M, et al. Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: a Mechanisms of the Development of Allergy (MeDALL) Seminar. J Allergy Clin Immunol 2012; 129: 943-954.
7. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2008. Updated December 2009. www.ginasthma.org/uploads/users/files/GINA_Report2011_May4.pdf.
8. Koolen BB, Pijnenburg MWH, Brackel HJL, et al. Comparing Global Initiative for Asthma (GINA) criteria with the Childhood Asthma Control Test (C-ACT) and Asthma Control Test (ACT). Eur Respir J 2011; 38: 561-566.
9. Klok T, Kaptein AA, Duiverman EJ, et al. High inhaled corticosteroids adherence in childhood asthma: the role of medication beliefs. Eur Respir J 2012; [Epub ahead of print DOI: 10.1183/09031936.00191511].
10. Boyd M, Lasserson TJ, McKean MC, et al. Interventions for educating children who are at risk of asthma-related emergency department attendance. Cochrane Database Syst Rev 2009; 2: CD001290.
11. Lai CK, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2009; 64: 476-483.
12. Gore FM, Bloem PJ, Patton GC, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet 2011; 377: 2093-2102.
13. To T, Wang C, Guan J, et al. What is the lifetime risk of physiciandiagnosed asthma in Ontario, Canada? Am J Respir Crit Care Med 2010; 181: 337-343.
14. Duggan EM, Sturley J, Fitzgerald AP, et al. The 2002-2007 trends of prevalence of asthma, allergic rhinitis and eczema in Irish schoolchildren. Pediatr Allergy Immunol 2012; [Epub ahead of print DOI: 10.1111/j.1399-3038.2012.01291.x].
15. Thomas A, Lemanske RF Jr, Jackson DJ. Approaches to stepping up and stepping down care in asthmatic patients. J Allergy Clin Immunol 2011; 128: 915-924.
16. Bonfield TL, Ross KR. Asthma heterogeneity and therapeutic options from the clinic to the bench. Curr Opin Allergy Clin Immunol 2012; 12: 60-67.
17. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545-554.
18. Lang A, Carlsen KH, Haaland G, et al. Severe asthma in childhood: assessed in 10 year olds in a birth cohort study. Allergy 2008; 63: 1054-1060.
19. Bush A, Zar HJ. WHO universal definition of severe asthma. Curr Opin Allergy Clin Immunol 2011; 11: 115-121.
20. Bossley CJ, Saglani S, Kavanagh C, et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. Eur Respir J 2009; 34: 1052-1059.
21. Bush A, Hedlin G, Carlsen KH, et al. Severe childhood asthma: a common international approach? Lancet 2008; 372: 1019-1021.
22. 2LEN initiative. Eur Respir J 2010; 36: 196-201.
23. Konradsen JR, Nordlund B, Lidegran M, et al. Problematic severe asthma: a proposed approach to identifying children who are severely resistant to therapy. Pediatr Allergy Immunol 2011; 22: 9-18.
24. Bush A, Saglani S. Management of severe asthma in children. Lancet 2010; 376: 814-825.
25. Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011; 127: 382-389.
26. Nordlund B, Konradsen J, Pedroletti C, et al. The clinical benefit of evaluating health-related quality-of-life in children with problematic severe asthma. Acta Paediatr 2011; 100: 1454-1460.
27. Bush A, Pedersen S, Hedlin G, et al. Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where? Eur Respir J 2011; 38: 947-958.
28. Bracken M, Fleming L, Hall P, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child 2009; 94: 780-784.
29. Lødrup Carlsen KC, Hedlin G, Bush A, et al. Assessment of problematic severe asthma in children. Eur Respir J 2011; 37: 432-440.
30. Koster ES, Wijga AH, Koppelman GH, et al. Uncontrolled asthma at age 8: the importance of parental perception towards medication. Pediatr Allergy Immunol 2011; 22: 462-468.
31. Wu AC, Tantisira K, Li L, et al. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest 2011; 140: 100-107.
32. 2LEN paper. Allergy 2010; 65: 1212-1221.
33. Boulay ME, Boulet LP. The relationships between atopy, rhinitis and asthma: pathophysiological considerations. Curr Opin Allergy Clin Immunol 2003; 3: 51-55.
34. de Groot EP, Nijkamp A, Duiverman EJ, et al. Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax 2012; 67: 582-587.
35. Chawes BL, Bonnelykke K, Kreiner-Moller E, et al. Children with allergic and nonallergic rhinitis have a similar risk of asthma. J Allergy Clin Immunol 2010; 126: 567-573.
36. Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe - an underestimated disease. A GA(2)LEN study. Allergy 2011; 66: 1216-1223.
37. Thakkar K, Boatright RO, Gilger MA, et al. Gastroesophageal reflux and asthma in children: a systematic review. Pediatrics 2010; 125: e925-e930.
38. Stordal K, Johannesdottir GB, Bentsen BS, et al. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child 2005; 90: 956-960.
39. Holbrook JT, Wise RA, Gold BD, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA 2012; 307: 373-381.
40. Low K, Lau KK, Holmes P, et al. Abnormal vocal cord function in difficult-to-treat asthma. Am J Respir Crit Care Med 2011; 184: 50-56.
41. Ayres JG, Mansur AH. Vocal cord dysfunction and severe asthma: considering the total airway. Am J Respir Crit Care Med 2011; 184: 2-3.
42. Forno E, Lescher R, Strunk R, et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol 2011; 127: 741-749.
43. Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol 2011; 127: 1486-1493.
44. Cibella F, Cuttitta G, La Grutta S, et al. A cross-sectional study assessing the relationship between BMI, asthma, atopy, and eNO among schoolchildren. Ann Allergy Asthma Immunol 2011; 107: 330-336.
45. Quinto KB, Zuraw BL, Poon KY, et al. The association of obesity and asthma severity and control in children. J Allergy Clin Immunol 2011; 128: 964-969.
46. Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008; 178: 682-687.
47. Cottrell L, Neal WA, Ice C, et al. Metabolic abnormalities in children with asthma. Am J Respir Crit Care Med 2011; 183: 441-448.
48. Gupta A, Sjoukes A, Richards D, et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med 2011; 184: 1342-1349.
49. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010; 126: 52-58.
50. Chinellato I, Piazza M, Sandri M, et al. Serum vitamin D levels and exercise-induced bronchoconstriction in children with asthma. Eur Respir J 2011; 37: 1366-1370.
51. Chung KF, Bel EH, Wenzel S., eds. Difficult-to-Treat Severe asthma. Eur Respir Monogr 2011; 51: 1-308.
52. Holt PG, Strickland DH, Sly PD. Virus infection and allergy in the development of asthma: what is the connection? Curr Opin Allergy Clin Immunol 2012; 12: 151-157.
53. Jackson DJ, Evans MD, Gangnon RE, et al. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med 2012; 185: 281-285.
54. Martinez FD. New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol 2011; 128: 939-945.
55. Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010; 376: 826-834.
56. Jackson DJ, Sykes A, Mallia P, et al. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011; 128: 1165-1174.
57. Strickland DH, Holt PG. T regulatory cells in childhood asthma. Trends Immunol 2011; 32: 420-427.
58. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol 2010; 11: 577-584.
59. Locksley RM. Asthma and allergic inflammation. Cell 2010; 140: 777-783.
60. Ramakrishna L, de Vries VC, Curotto de Lafaille MA. Crossroads in the lung: immune cells and tissue interactions as determinants of allergic asthma. Immunol Res 2012; [Epub ahead of print DOI: 10.1007/s12026-012-8296-4].
61. Gaston B. The biochemistry of asthma. Biochim Biophys Acta 2011; 1810: 1017-1024.
62. Monteseirin J. Neutrophils and asthma. J Investig Allergol Clin Immunol 2009; 19: 340-354.
63. Durrani SR, Viswanathan RK, Busse WW. What effect does asthma treatment have on airway remodeling? Current perspectives. J Allergy Clin Immunol 2011; 128: 439-448.
64. Fitzpatrick AM, Teague WG. Progressive airflow limitation is a feature of children with severe asthma. J Allergy Clin Immunol 2011; 127: 282-284.
65. Borres MP, Ebisawa M, Eigenmann PA. Use of allergen components begins a new era in pediatric allergology. Pediatr Allergy Immunol 2011; 22: 454-461.
66. Larche M. T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol 2011; 352: 107-119.
67. Madhurantakam C, Nilsson OB, Uchtenhagen H, et al. Crystal structure of the dog lipocalin allergen Can f 2: implications for cross-reactivity to the cat allergen Fel d 4. J Mol Biol 2010; 401: 68-83.
68. Saarelainen SA, Kinnunen TT, Buhot C, et al. Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues. Immunology 2008; 123: 358-366.
69. Voehringer D. Basophils in allergic immune responses. Curr Opin Immunol 2011; 23: 789-793.
70. Karasuyama H, Obata K, Wada T, et al. Newly appreciated roles for basophils in allergy and protective immunity. Allergy 2011; 66: 1133-1141.
71. Taylor DR. Using biomarkers in the assessment of airways disease. J Allergy Clin Immunol 2011; 128: 927-934.
72. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012; 129: Suppl. 3, S9-S23.
73. Busse WW. Asthma diagnosis and treatment: filling in the information gaps. J Allergy Clin Immunol 2011; 128: 740-750.
74. van Dalen C, Harding E, Parkin J, et al. Suitability of forced expiratory volume in 1 second/forced vital capacity vs percentage of predicted forced expiratory volume in 1 second for the classification of asthma severity in adolescents. Arch Pediatr Adolesc Med 2008; 162: 1169-1174.
75. Fitzpatrick AM, Gaston BM, Erzurum SC, et al. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol 2006; 118: 1218-1225.
76. Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181: 1033-1041.
77. Cockcroft DW. Direct challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138: Suppl. 2, 18S-24S.
78. Anderson SD. Indirect challenge tests: airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010; 138: Suppl. 2, 25S-30S.
79. Lex C, Payne DN, Zacharasiewicz A, et al. Sputum induction in children with difficult asthma: safety, feasibility, and inflammatory cell pattern. Pediatric Pulmonol 2005; 39: 318-324.
80. Drews AC, Pizzichini MM, Pizzichini E, et al. Neutrophilic airway inflammation is a main feature of induced sputum in nonatopic asthmatic children. Allergy 2009; 64: 1597-1601.
81. Kulkarni N, Ragazzo V, Costella S, et al. Eosinophilic airway inflammation is increased in children with asthma and food allergies. Pediatr Allergy Immunol 2012; 23: 28-33.
82. Fleming L, Wilson N, Regamey N, et al. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax 2012; 67: 193-198.
83. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: 199-208.
84. van de Kant KD, Jansen MA, Klaassen EM, et al. Elevated inflammatory markers at preschool age precede persistent wheezing at school age. Pediatr Allergy Immunol 2012; 23: 259-264.
85. Zeiger RS, Schatz M, Zhang F, et al. Association of exhaled nitric oxide to asthma burden in asthmatics on inhaled corticosteroids. J Asthma 2011; 48: 8-17.
86. Zeiger RS, Schatz M, Zhang F, et al. Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol 2011; 128: 412-414.
87. Pijnenburg MW, Bakker EM, Hop WC, et al. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172: 831-836.
88. de Jongste JC, Carraro S, Hop WC, et al. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009; 179: 93-97.
89. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372: 1065-1072.
90. Waibel V, Ulmer H, Horak E. Assessing asthma control: symptom scores, GINA levels of asthma control, lung function, and exhaled nitric oxide. Pediatric Pulmonol 2012; 47: 113-118.
91. Stern G, de Jongste J, van der Valk R, et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol 2011; 128: 293-300.
92. Aujla SJ, Ross KR, Chmiel JF, et al. Airway molecular phenotypes in pediatric asthma. Curr Opin Allergy Clin Immunol 2011; 11: 122-126.
93. Caballero Balanza S, Martorell Aragones A, Cerda Mir JC, et al. Leukotriene B4 and 8-isoprostane in exhaled breath condensate of children with episodic and persistent asthma. J Investig Allergol Clin Immunol 2010; 20: 237-243.
94. Profita M, Montuschi P, Bonanno A, et al. Novel perspectives in the detection of oral and nasal oxidative stress and inflammation in pediatric united airway diseases. Int J Immunopathol Pharmacol 2010; 23: 1211-1219.
95. Sachs-Olsen C, Sanak M, Lang AM, et al. Eoxins: a new inflammatory pathway in childhood asthma. J Allergy Clin Immunol 2010; 126: 859-867.
96. Carraro S, Cogo PE, Isak I, et al. EIA and GC/MS analysis of 8isoprostane in EBC of children with problematic asthma. Eur Respir J 2010; 35: 1364-1369.
97. Bloemen K, Van Den Heuvel R, Govarts E, et al. A new approach to study exhaled proteins as potential biomarkers for asthma. Clin Exp Allergy 2011; 41: 346-356.
98. Dompeling E, Jobsis Q. Proteomics of exhaled breath condensate: a realistic approach in children with asthma? Clin Exp Allergy 2011; 41: 299-301.
99. Sinha A, Krishnan V, Sethi T, et al. Metabolomic signatures in nuclear magnetic resonance spectra of exhaled breath condensate identify asthma. Eur Respir J 2012; 39: 500-502.
100. Saude EJ, Skappak CD, Regush S, et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol 2011; 127: 757-764.
101. Mattarucchi E, Baraldi E, Guillou C. Metabolomics applied to urine samples in childhood asthma: differentiation between asthma phenotypes and identification of relevant metabolites. Biomed Chromatogr 2012; 26: 89-94.
102. Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol 2010; 126: 545-551.
103. Brockmann PE, Castro-Rodriguez JA, Holmgren NL, et al. Urinary leukotriene excretion profile in children with exercise-induced asthma compared with controls: a preliminary study. Allergol Immunopathol (Madr) 2011; 40: 181-186.
104. Wedes SH, Wu W, Comhair SA, et al. Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children. J Pediatr 2011; 159: 248-255.
105. Bussink AP, Speijer D, Aerts JM, et al. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 2007; 177: 959-970.
106. Bargagli E, Olivieri C, Margollicci M, et al. Serum chitotriosidase levels in patients with allergic and non-allergic asthma. Respiration 2010; 79: 437-438.
107. Chupp GL, Lee CG, Jarjour N, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007; 357: 2016-2027.
108. Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011; 73: 479-501.
109. Bara I, Ozier A, Girodet PO, et al. Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med 2012; 185: 715-722.
110. Letuve S, Kozhich A, Arouche N, et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008; 181: 5167-5173.
111. Otsuka K, Matsumoto H, Niimi A, et al. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration 2012; 83: 507-519.
112. Douros K, Alexopoulou E, Nicopoulou A, et al. Bronchoscopic and high-resolution CT scan findings in children with chronic wet cough. Chest 2011; 140: 317-323.
113. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of highresolution CT scans in severe asthma. Chest 2009; 136: 1521-1528.
114. Gupta S, Siddiqui S, Haldar P, et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax 2010; 65: 775-781.
115. Tashkin DP, de Lange EE. Imaging of the distal airways. J Allergy Clin Immunol 2009; 124: Suppl. 6, S78-S83.
116. Aysola R, de Lange EE, Castro M, et al. Demonstration of the heterogeneous distribution of asthma in the lungs using CT and hyperpolarized helium-3 MRI. J Magn Reson Imaging 2010; 32: 1379-1387.
117. Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy 2012; 67: 18-24.
118. Frith J, Fleming L, Bossley C, et al. The complexities of defining atopy in severe childhood asthma. Clin Exp Allergy 2011; 41: 948-953.
119. Gronlund H, Adedoyin J, Reininger R, et al. Higher immunoglobulin E antibody levels to recombinant Fel d 1 in cat-allergic children with asthma compared with rhinoconjunctivitis. Clin Exp Allergy 2008; 38: 1275-1281.
120. Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy 2010; 40: 1442-1460.
121. Asarnoj A, Moverare R, Ostblom E, et al. IgE to peanut allergen components: relation to peanut symptoms and pollen sensitization in 8-year-olds. Allergy 2010; 65: 1189-1195.
122. Nordlund B, Konradsen JR, Kull I, et al. IgE antibodies to animalderived lipocalin, kallikrein and secretoglobin are markers of bronchial inflammation in severe childhood asthma: airway diseases. Allergy 2012; 67: 661-669.
123. Johansson SG, Nopp A, van Hage M, et al. Passive IgE-sensitization by blood transfusion. Allergy 2005; 60: 1192-1199.
124. Dahlen B, Nopp A, Johansson SG, et al. Basophil allergen threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthma. Clin Exp Allergy 2011; 41: 1091-1097.
125. Konradsen JR, Nordlund B, Nilsson OB, et al. High basophil allergen sensitivity (CD-sens) is associated with severe allergic asthma in children. Pediatr Allergy Immunol 2012; 23: 376-384.
126. Siracusa MC, Saenz SA, Hill DA, et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 2011; 477: 229-233.
127. Bush A, Frey U, Teague WG. Special problems of severe asthma in childhood. Eur Respir Monogr 2011; 51: 59-81.
128. Boulet LP, Fitzgerald JM, Levy ML, et al. A guide to the translation of Global Initiative for Asthma (GINA) strategy into improved care. Eur Respir J 2012; 39: 1220-1229.
129. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975-985.
130. Levy ML, Thomas M, Small I, et al. Summary of the 2008 BTS/ SIGN British Guideline on the management of asthma. Prim Care Respir J 2009; 18: Suppl. 1, S1-16.
131. Brand PLP, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096-1110.
132. Zeiger RS, Mauger D, Bacharier LB, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365: 1990-2001.
133. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, doubleblind, placebo-controlled trial. Lancet 2011; 377: 650-657.
134. Turpeinen M, Nikander K, Pelkonen AS, et al. Daily versus asneeded inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 2008; 93: 654-659.
135. Turpeinen M, Pelkonen AS, Nikander K, et al. Bone mineral density in children treated with daily or periodical inhaled budesonide: the Helsinki Early Intervention Childhood Asthma study. Pediatr Res 2010; 68: 169-173.
136. Turpeinen M, Raitio H, Pelkonen AS, et al. Skin thickness in children treated with daily or periodical inhaled budesonide for mild persistent asthma. The Helsinki early intervention childhood asthma study. Pediatr Res 2010; 67: 221-225.
137. Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 2006; 61: 376-382.
138. Subrata LS, Bizzintino J, Mamessier E, et al. Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J Immunol 2009; 183: 2793-2800.
139. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-1015.
140. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124: 1210-1216.
141. Pavord ID, Bush A. Anti-IgE for asthma in inner-city children. N Engl J Med 2011; 364: 2556-2557.
142. Busse WW, Gergen PJ, Calatroni A. Anti IgE for asthma in innercity children: authors response. N Engl J Med 2011; 364: 2557-2558.
143. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715-1726.
144. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-1431.
145. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
146. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
147. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
148. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104: 15858-15863.
149. Edlmayr J, Niespodziana K, Linhart B, et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009; 182: 6298-6306.
150. Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012; 129: 1290-1296.
151. Krishnan JA, Bender BG, Wamboldt FS, et al. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. J Allergy Clin Immunol 2012; 129: 112-118.
152. Klok T, Brand PL, Bomhof-Roordink H, et al. Parental illness perceptions and medication perceptions in childhood asthma, a focus group study. Acta Paediatr 2011; 100: 248-252.
153. Caudri D, Wijga AH, Smit HA, et al. Asthma symptoms and medication in the PIAMA birth cohort: evidence for under and overtreatment. Pediatr Allergy Immunol 2011; 22: 652-659.
154. Mackay D, Haw S, Ayres JG, et al. Smoke-free legislation and hospitalizations for childhood asthma. N Engl J Med 2010; 363: 1139-1145.
155. Renzetti G, Silvestre G, D'Amario C, et al. Less air pollution leads to rapid reduction of airway inflammation and improved airway function in asthmatic children. Pediatrics 2009; 123: 1051-1058.